Literature DB >> 31761938

Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives.

Konstantinos Papamichael1, Adam S Cheifetz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31761938      PMCID： PMC7346892          DOI： 10.1093/ecco-jcc/jjz191

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  5 in total

1.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.

Authors:  Nicholas A Kennedy; Graham A Heap; Harry D Green; Benjamin Hamilton; Claire Bewshea; Gareth J Walker; Amanda Thomas; Rachel Nice; Mandy H Perry; Sonia Bouri; Neil Chanchlani; Neel M Heerasing; Peter Hendy; Simeng Lin; Daniel R Gaya; J R Fraser Cummings; Christian P Selinger; Charlie W Lees; Ailsa L Hart; Miles Parkes; Shaji Sebastian; John C Mansfield; Peter M Irving; James Lindsay; Richard K Russell; Timothy J McDonald; Dermot McGovern; James R Goodhand; Tariq Ahmad
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-02-27

2.  Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.

Authors:  Amit Assa; Manar Matar; Dan Turner; Efrat Broide; Batia Weiss; Oren Ledder; Anat Guz-Mark; Firas Rinawi; Shlomi Cohen; Chani Topf-Olivestone; Ron Shaoul; Baruch Yerushalmi; Raanan Shamir
Journal:  Gastroenterology       Date:  2019-06-10       Impact factor: 22.682

3.  Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.

Authors:  Konstantinos Papamichael; Anna Juncadella; Danny Wong; Shana Rakowsky; Lindsey A Sattler; James P Campbell; Byron P Vaughn; Adam S Cheifetz
Journal:  J Crohns Colitis       Date:  2019-08-14       Impact factor: 9.071

4.  Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.

Authors:  Bella Ungar; Tal Engel; Doron Yablecovitch; Adi Lahat; Alon Lang; Benjamin Avidan; Ofir Har-Noy; Dan Carter; Nina Levhar; Limor Selinger; Sandra Neuman; Ola Haj Natour; Miri Yavzori; Ella Fudim; Orit Picard; Uri Kopylov; Yehuda Chowers; Timna Naftali; Efrat Broide; Eyal Shachar; Rami Eliakim; Shomron Ben-Horin
Journal:  Am J Gastroenterol       Date:  2018-06-05       Impact factor: 10.864

5.  Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.

Authors:  Bram Verstockt; Gitte Moors; Sumin Bian; Thomas Van Stappen; Gert Van Assche; Séverine Vermeire; Ann Gils; Marc Ferrante
Journal:  Aliment Pharmacol Ther       Date:  2018-08-15       Impact factor: 8.171
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.